Treating Hyperexcitability in AD With Levetiracetam

This study is testing whether a drug called levetiracetam — already approved to treat seizures — can reduce abnormal brain overactivity seen in early Alzheimer's disease. Researchers believe that calming this overactivity may help slow the progression of memory decline in people with early-stage Alzheimer's. **You may be eligible if...** - You are 50–90 years old - You have an early Alzheimer's disease diagnosis meeting standard diagnostic criteria - You score 20 or above on the MMSE (a standard memory test) - You have tested positive for amyloid (via spinal fluid or brain PET scan) - You have been on a stable dose of memory medications for at least 4 weeks - Healthy volunteers aged 50–90 may also qualify for the control group **You may NOT be eligible if...** - Your memory condition is not Alzheimer's disease - You have a history of epilepsy or seizures - You have significant psychiatric or other neurological disorders - You are unable to tolerate a spinal fluid collection or brain scan Talk to your doctor to see if this trial is right for you.